FDA Orange Book
Is there a generic for Rinvoq Lq?
Rinvoq Lq contains upadacitinib. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Rinvoq Lq (upadacitinib). The Orange Book shows its last listed patent expires October 17, 2036 and its last listed exclusivity ends April 26, 2031.
Run it in Rivvi
Map Rinvoq Lq and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Rinvoq Lq products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| solution, oral | 1MG/ML | Marketed (Rx) | None | 0 | None |
NDA 218347, held by ABBVIE INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Rinvoq Lq patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 8962629 | January 15, 2031 | Drug substance | U-3946 | 218347 |
| 8962629 | January 15, 2031 | Drug substance | U-3945 | 218347 |
| RE47221 | August 16, 2033 | Drug substance | None | 218347 |
| 12365689 | October 17, 2036 | Method of use | U-3945 | 218347 |
| 9951080 | October 17, 2036 | Drug substance | None | 218347 |
| 10981923 | October 17, 2036 | Drug substance | None | 218347 |
| 11680069 | October 17, 2036 | Drug substance | None | 218347 |
| 12110298 | October 17, 2036 | Drug substance | None | 218347 |
| 11718627 | October 17, 2036 | Drug substance | None | 218347 |
| 11661425 | October 17, 2036 | Drug substance | None | 218347 |
| 11773105 | October 17, 2036 | Drug substance | None | 218347 |
| 11186584 | October 17, 2036 | Drug substance | None | 218347 |
Rinvoq Lq exclusivity
| Code | Meaning | Expires | NDA |
|---|---|---|---|
| NP | New product | April 26, 2027 | 218347 |
| ODE-481 | Orphan drug exclusivity | April 26, 2031 | 218347 |
Rinvoq Lq NDC codes
Questions
Is there a generic for Rinvoq Lq?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Rinvoq Lq (upadacitinib). The Orange Book shows its last listed patent expires October 17, 2036 and its last listed exclusivity ends April 26, 2031.
What is the generic name for Rinvoq Lq?
The active ingredient in Rinvoq Lq is upadacitinib, per the FDA Orange Book.
When does the Rinvoq Lq patent expire?
The last patent listed for Rinvoq Lq in the Orange Book expires October 17, 2036. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.